Lonza is a multinational company headquartered in Basel, Switzerland, with a significant presence in the United States. It was founded in 1897 as a small chemical manufacturing company and has since evolved into a leading global supplier to the pharmaceutical, biotech, and specialty ingredients markets. Lonza offers a range of products and services, including custom development and manufacturing of active pharmaceutical ingredients (APIs), drug product intermediates, and biologics.

The company also provides a variety of services in cell and gene therapy, including process development, manufacturing, and analytics support. In addition, Lonza produces specialty chemicals, microbial control solutions, and nutritional ingredients for various industries. Lonza operates on a global scale with manufacturing facilities and offices in more than 35 countries.

The company has established several noteworthy subsidiaries, joint ventures, and partnerships. Lonza's joint ventures include Ibex™ Solutions, a biopharmaceutical development and manufacturing platform, and Lonza-Capsugel, a collaboration focused on drug delivery technologies. Notably, Lonza acquired Capsugel, a leading provider of dosage forms and solutions for the healthcare industry, in 2017.

In terms of market position, Lonza is a key player in the global life sciences industry. The company reported net sales of CHF 5. 9 billion (approximately USD 6.

6 billion) in 2019. It competes with other multinational companies such as Thermo Fisher Scientific, Merck KGaA, and Catalent. Lonza has achieved several significant milestones over the years.

The acquisition of Capsugel expanded its capabilities in oral dosage forms and enhanced its overall integrated offerings. Additionally, Lonza's investments in cell and gene therapy manufacturing facilities have positioned it as a leader in this rapidly growing field. As of the latest updates, Lonza remains focused on its strategic priorities, including enhancing its healthcare business, leveraging digitalization, and expanding its capabilities in new and emerging markets.

The company continues to invest in research and development, innovation, and operational excellence to meet the evolving needs of its customers. In conclusion, Lonza is a global leader in the life sciences industry, offering a wide range of products and services. With a strong market position, notable subsidiaries, and strategic partnerships, the company is well-positioned for continued growth and innovation